
Opinion|Videos|April 30, 2025
CHE Subtypes
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) presents in various clinical and etiologic subtypes, including irritant and allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis, with clinical manifestations ranging from hyperkeratotic to vesicular forms.
Advertisement
Video content above is prompted by the following:
CHE Morphological and Etiological Subtypes
Key Themes:
- Etiologic subtypes: Its 4 main categories are irritant contact dermatitis (most common), allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis.
- Clinical morphologies: Include hyperkeratotic, acute recurrent vesicular, nummular eczema, and pulpitis presentations, all with distinct characteristics.
- Overlapping presentations: Most patients have mixed etiologies and clinical features rather than single, pure forms.
Notable Insights:
Dr Chovatiya noted that "etiologic subtypes don't predict specific clinical subtypes and clinical subtypes don't specifically predict etiologic subtypes," highlighting the complex presentation of CHE.
Advertisement
Related to this article

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5

